Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC, Matei DE, Bonini MG, Munshi HG, Hashizume R, Wu JD, Zhang B, James CD, Chen P, Kocherginsky M, Horbinski C, Cameron MD, Grigorescu AA, Yamini B, Lukas RV, Schiltz GE, Wainwright DA. Bollu LR, et al. Among authors: kocherginsky m. J Med Chem. 2022 Dec 8;65(23):15642-15662. doi: 10.1021/acs.jmedchem.2c00771. Epub 2022 Nov 21. J Med Chem. 2022. PMID: 36410047 Free PMC article.
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.
Ladomersky E, Scholtens DM, Kocherginsky M, Hibler EA, Bartom ET, Otto-Meyer S, Zhai L, Lauing KL, Choi J, Sosman JA, Wu JD, Zhang B, Lukas RV, Wainwright DA. Ladomersky E, et al. Among authors: kocherginsky m. Front Pharmacol. 2019 Mar 27;10:200. doi: 10.3389/fphar.2019.00200. eCollection 2019. Front Pharmacol. 2019. PMID: 30971917 Free PMC article.
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer JJ, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn DH, Wainwright DA. Ladomersky E, et al. Among authors: kocherginsky m. Clin Cancer Res. 2020 Oct 1;26(19):5232-5245. doi: 10.1158/1078-0432.CCR-19-3874. Epub 2020 Jun 16. Clin Cancer Res. 2020. PMID: 32546647 Free PMC article.
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Cowan M, et al. Among authors: kocherginsky m. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. Gynecol Oncol. 2021. PMID: 34419285 Clinical Trial.
Glioblastoma as an age-related neurological disorder in adults.
Kim M, Ladomersky E, Mozny A, Kocherginsky M, O'Shea K, Reinstein ZZ, Zhai L, Bell A, Lauing KL, Bollu L, Rabin E, Dixit K, Kumthekar P, Platanias LC, Hou L, Zheng Y, Wu J, Zhang B, Hrachova M, Merrill SA, Mrugala MM, Prabhu VC, Horbinski C, James CD, Yamini B, Ostrom QT, Johnson MO, Reardon DA, Lukas RV, Wainwright DA. Kim M, et al. Among authors: kocherginsky m. Neurooncol Adv. 2021 Sep 4;3(1):vdab125. doi: 10.1093/noajnl/vdab125. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34647022 Free PMC article. Review.
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Saleiro D, Wen JQ, Kosciuczuk EM, Eckerdt F, Beauchamp EM, Oku CV, Blyth GT, Fischietti M, Ilut L, Colamonici M, Palivos W, Atsaves PA, Tan D, Kocherginsky M, Weinberg RS, Fish EN, Crispino JD, Hoffman R, Platanias LC. Saleiro D, et al. Among authors: kocherginsky m. Nat Commun. 2022 Apr 1;13(1):1750. doi: 10.1038/s41467-022-29381-7. Nat Commun. 2022. PMID: 35365653 Free PMC article.
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area.
Mina A, Galvez C, Karmali R, Mulcahy M, Mi X, Kocherginsky M, Gurley MJ, Katam N, Gradishar W, Altman JK, Ison MG, Tsarwhas D, George C, Winter JN, Gordon LI, Wehbe FH, Platanias LC. Mina A, et al. Among authors: kocherginsky m. Cancers (Basel). 2022 Apr 28;14(9):2209. doi: 10.3390/cancers14092209. Cancers (Basel). 2022. PMID: 35565336 Free PMC article.
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, Tanner EJ, Fleming GF, Moroney JW, Pant A, Akasha AM, Davuluri RV, Kocherginsky M, Zhang B, Matei D. Chen S, et al. Among authors: kocherginsky m. J Clin Invest. 2022 Jul 15;132(14):e158800. doi: 10.1172/JCI158800. J Clin Invest. 2022. PMID: 35671108 Free PMC article. Clinical Trial.
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.
Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, Schilder J, O'Shea KL, Kocherginsky M, Zhang B, Matei D. Barber EL, et al. Among authors: kocherginsky m. Cancer Res Commun. 2022 Oct;2(10):1293-1303. doi: 10.1158/2767-9764.crc-22-0147. Epub 2022 Oct 28. Cancer Res Commun. 2022. PMID: 36388466 Free PMC article. Clinical Trial.
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors.
Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET, Kocherginsky M, Platanias LC, Saleiro D. Fenton SE, et al. Among authors: kocherginsky m. Mol Cancer Res. 2023 Apr 1;21(4):332-344. doi: 10.1158/1541-7786.MCR-22-0684. Mol Cancer Res. 2023. PMID: 36573964 Free PMC article.
153 results